Submit new drug application (NDA) for relacorilant
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Nov 2021
- Due
- 30 Jun 2023
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“new drug application (NDA) submission expected in the second quarter of 2023”
What we found
Evidence strength A What the grades mean
The company failed to submit the NDA by the Q2 2023 deadline, subsequently updating its guidance in August 2023 to expect the submission in the second quarter of 2024.
-
A Corcept Therapeutics Inc. 8-K filed 2023-08-02
“new drug application (NDA) submission expected in the second quarter of 2024” ✓ confirmed on the page
Market reaction: the shares moved +26.9% against the S&P 500 over the three sessions around the disclosure (1 Aug 2023 to 4 Aug 2023). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +550 days
- 4 versions
-
Version 1 · original · stated 3 Nov 2021
Deadline 30 Jun 2023 (“in the second quarter of 2023”) · wording expected
-
Version 2 · stated 5 May 2022
Deadline 31 Dec 2023 (“second half 2023”) · wording expected
“new drug application (NDA) submission now expected in second half 2023”
-
Version 3 · stated 2 Aug 2023
Deadline 30 Jun 2024 (“second quarter of 2024”) · wording expected
“new drug application (NDA) submission expected in the second quarter of 2024”
-
Version 4 · stated 29 Jul 2024
Deadline 31 Dec 2024 (“the fourth quarter”) · wording expected
“Relacorilant New Drug Application (NDA) – NDA submission for Cushing’s syndrome expected in the fourth quarter”
-
Version 5 · stated 31 Mar 2025
Deadline 30 Sep 2025 (“in the third quarter”) · wording expected
“We expect to submit our NDA in the third quarter”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- NDA submission
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CORT-002842 · Corrections policy